Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation

Condition(s) targeted: Stable Angina

Intervention: Diltiazem treated group (Drug); Bisoprolol treated group (Drug); Candesartan treated group (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: Seoul National University Hospital

Overall contact:
Hae-Young Lee, MD, PhD, Phone: 82-10-4528-6160, Email: hylee612@snu.ac.kr

Treatments for stable angina includes drug therapy such as calcium-channel blocker, beta blocker, and ACEI/ARB. To obtain good prognosis in patients with coronary artery disease,preventing or correcting the progression of atherosclerosis and dyslipidemia is more important than relieving angina symptom. Dysfunction of microvessel is one of the most important factor in patients with coronary artery disease. Recently, we developed the new non-invasive method of evaluating the microvessel in fundus. With this methods, we will compare the effect of each drug (beta blocker, CCB, ARB).

Official title: Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Wall to lumen ratio of fundus vessel

Secondary outcome:

lipid parameter

Serum markers of inflammation

Change of nitrate need

Minimum age: 30 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Stable angina patients whose coronary lesions is confirmed by angiography or receives

PCI

- Unstable Angina/NSTEMI patients who completed PCI for main lesions

- Either systolic > 130mmHg or diastolic > 80mmHg, or patients with anti-hypertensive

drugs Exclusion Criteria:

- STEMI patients within one month

- Variant Angina

- Liver function abnormality or renal failure

- History of Hypersensitivity to testing drugs

- Severe heart failure(NYHA class>3) or uncorrectable hematologic disease

- Woman possible to be pregnant

- Uncontrolled diabetes

- Expected life span < one year

Hae-Young Lee, MD, PhD, Phone: 82-10-4528-6160, Email: hylee612@snu.ac.kr

Seoul National University Hospital, Seoul, Korea, Republic of; Not yet recruiting
Hyo-Soo Kim, MD, PhD, Principal Investigator
Hae-Young Lee, MD,PhD, Sub-Investigator

Starting date: September 2013
Last updated: December 15, 2013